<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289558</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00100364</org_study_id>
    <secondary_id>R01HL130763</secondary_id>
    <nct_id>NCT04289558</nct_id>
  </id_info>
  <brief_title>Nitrite Infusion in Children With Malaria</brief_title>
  <official_title>Safety, Feasibility, and Endothelial Effects of Sodium Nitrite Infusion in Children With Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of intravenous sodium nitrite in African&#xD;
      children who have moderately severe malaria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, open-label, dose-escalation study that will enroll up to 24 patients&#xD;
      total, using a 3+3 dose escalation design, with 3 to 6 patients per dose level at up to 4&#xD;
      sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). At each dose level patients&#xD;
      with moderately severe malaria will receive a single 60-minute intravenous infusion of sodium&#xD;
      nitrite in 0.9% sodium chloride. Blood pressure and methemoglobin levels will be closely&#xD;
      monitored during the infusion and for 24 hours post infusion.&#xD;
&#xD;
      This study will allow a preliminary analysis of the safety of intravenous sodium nitrite in&#xD;
      children with moderately severe malaria and is expected to provide preliminary data on its&#xD;
      effects on endothelial function. The hypothesis is that sodium nitrite infusion will be safe&#xD;
      at low dosage levels. Additionally, since deficiency of nitric oxide is linked to endothelial&#xD;
      dysfunction in malaria, there is the hypothesis that sodium nitrite will result in improved&#xD;
      markers of endothelial function.&#xD;
&#xD;
      Children are the largest group affected by falciparum malaria. The study population will be&#xD;
      male children residing in Tanzania, ages 4-10 years old diagnosed with moderately severe&#xD;
      malaria, who have been hospitalized for treatment of their malaria at Hubert Kairuki Medical&#xD;
      University in Dar es Salaam, Tanzania. Patients will receive standard anti-malaria and&#xD;
      supportive care treatment. The study will enroll up to 24 subjects.&#xD;
&#xD;
      Participants will receive a single intravenous infusion of sodium nitrite diluted in 0.9%&#xD;
      sodium chloride. The infusion will be administered over 60 minutes with an infusion pump.&#xD;
      Escala-ting doses of sodium nitrite will be administered to patients in 4 dose level cohorts.&#xD;
      Patients will be sequentially enrolled starting at the lowest dose level. Individual patients&#xD;
      at the same dose level will also be enrolled sequentially, such that the next patient will&#xD;
      not receive treatment until completion of a 24- hour safety monitoring period for the prior&#xD;
      patient. Dose assign-ment will be based on the order of study enrollment. The maximum&#xD;
      tolerated dose (MTD) is the highest dose level wherein ≤ 1 of 6 evaluable patients&#xD;
      experiences dose limiting toxicity (DLT). If the MTD is exceeded at the first dose level,&#xD;
      then dosing will cease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    current grant expiration in May, insufficient funds remaining, travel restrictions, COVID-19&#xD;
    restrictions in Tanzania, etc.&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by number of subjects with at least one adverse event</measure>
    <time_frame>48 hours post infusion</time_frame>
    <description>Adverse events will be assessed according to the NIH's Table for Grading the Severity of Adult and Pediatric Adverse Events. Events will be numerically graded 1-5; 1 being a mild event and 5 being death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change in microvascular function/activation for each of the 4 dosing levels by linear regression</measure>
    <time_frame>48 hours post infusion</time_frame>
    <description>We will assess possible covariate relationships. A model will be developed that links the pharmacokinetics with the pharmacodynamic measures of endothelial function and activation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>Sodium Nitrite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 60-minute intravenous infusion of sodium nitrite in 0.9% sodium chloride at up to 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitrite</intervention_name>
    <description>Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). The dose amount will depend on when the participant enters the study</description>
    <arm_group_label>Sodium Nitrite</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent from parent or legal guardian&#xD;
&#xD;
          2. Males, &gt;4 to 10 years of age&#xD;
&#xD;
          3. Body weight &gt; 12 kg&#xD;
&#xD;
          4. Parasitemia with Plasmodium falciparum including:&#xD;
&#xD;
               1. Positive rapid diagnostic test result: AND&#xD;
&#xD;
               2. &gt;2,500 parasites/microliter by microscopy&#xD;
&#xD;
          5. Diagnosis of MSM, as follows:&#xD;
&#xD;
               1. Clinical syndrome consistent with malaria associated with documented fever&#xD;
                  (axillary temperature &gt;38C) or reported history of fever in the past 48 hours&#xD;
                  with no other cause present; AND&#xD;
&#xD;
               2. Exhibiting no WHO warning signs or criteria for SM [27]&#xD;
&#xD;
          6. A negative G6PD deficiency test (careSTART G6PD quantitative biosensor)&#xD;
&#xD;
          7. Requires inpatient parenteral treatment because of inability to tolerate oral therapy&#xD;
&#xD;
          8. Hemoglobin &gt; 8 g/dL (subjects with prior blood transfusion will be eligible).&#xD;
&#xD;
          9. Systolic blood pressure &gt; 85 mmHg&#xD;
&#xD;
         10. Baseline quantitative methemoglobin measurement less than 2%&#xD;
&#xD;
         11. Creatinine less than the upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female gender&#xD;
&#xD;
          2. Diagnosis of severe malaria&#xD;
&#xD;
          3. Presence of infection, or mixed infection, with non-falciparum strains of malaria&#xD;
&#xD;
          4. Signs of severe malaria[27], including 1 or more of the following:&#xD;
&#xD;
               -  impaired consciousness (Blantyre coma score &lt;3 in children)&#xD;
&#xD;
               -  prostration&#xD;
&#xD;
               -  multiple convulsions (&gt;2 within 24 hours)&#xD;
&#xD;
               -  acidosis (base deficit &gt;8 mEq/L or bicarbonate &lt;15 mmol/L or lactate &gt; 5 mmol/L)&#xD;
&#xD;
               -  hypoglycemia (blood glucose &lt; 40 mg/dL or &lt;2.2 mmol/L)&#xD;
&#xD;
               -  severe anemia (Hb &lt; 5g/dL )&#xD;
&#xD;
               -  renal impairment (serum creatinine &gt;265 uMol/L or 3 mg/dL; or blood urea &gt;20&#xD;
                  mmol/L)&#xD;
&#xD;
               -  jaundice (bilirubin &gt;50 umol or 3 mg/dL with parasite count &gt;100000/ µL)&#xD;
&#xD;
               -  pulmonary edema (including O2sat &lt;92% with RR &gt;30/min)&#xD;
&#xD;
               -  circulatory collapse or shock&#xD;
&#xD;
               -  significant bleeding&#xD;
&#xD;
               -  hyperparasitemia (&gt;10%)&#xD;
&#xD;
          5. Presence of concomitant non-malarial infection&#xD;
&#xD;
          6. Known G6PD deficiency&#xD;
&#xD;
          7. Known chronic illness including renal, cardiac, pulmonary, epilepsy&#xD;
&#xD;
          8. History of a reaction to a substance or medication consisting of dyspnea and cyanosis&#xD;
&#xD;
          9. History of trauma or bleeding in the 2 weeks prior to presentation&#xD;
&#xD;
         10. Clinical impression of disseminated intravascular coagulation&#xD;
&#xD;
         11. Subjects treated with parenteral anti-malarial drugs for more than 12 hours&#xD;
&#xD;
         12. Current use of drugs with oxidative potential (e.g., nitrates, dapsone, primaquine);&#xD;
             or drugs that cause hypotension.&#xD;
&#xD;
         13. Known allergic reactions to sodium nitrite injection&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Presence of G6PD deficiency increases the risk of RBC hemolysis occurring with administration of sodium nitrite and occurrence of methemoglobinemia. G6PD deficiency is an X-linked trait, thus males are either positive or negative, while females can exhibit a range of deficiency with heterozygotes commonly having an intermediate level</gender_description>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hubert Kairuki Memorial University</name>
      <address>
        <city>Dar es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>falciparum malaria</keyword>
  <keyword>malaria</keyword>
  <keyword>Africa</keyword>
  <keyword>Duke</keyword>
  <keyword>Tanzania</keyword>
  <keyword>sodium nitrite</keyword>
  <keyword>Phase I</keyword>
  <keyword>infectious disease</keyword>
  <keyword>hematology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

